Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

被引：0
|
作者：
Wei, Z. H. [1 ]
Le, P. H. [2 ,3 ,4 ]
Chiu, H. Y. [1 ]
Yeh, P. J. [3 ,5 ]
Chiu, C. T. [2 ,3 ,4 ]
Chiu, C. H. [3 ,6 ]
机构：
[1] Chang Gung Univ, Sch Med, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Linkou Branch, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp, Chang Gung Microbiota Therapy Ctr, Taoyuan, Taiwan
[4] Taiwan Assoc Study Small Intestinal Dis, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp, Div Pediat Gastroenterol, Linkou Branch, Dept Pediat, Taoyuan, Taiwan
[6] Chang Gung Mem Hosp, Div Pediat Infect Dis, Linkou Branch, Dept Pediat, Taoyuan, Taiwan
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P577
引用
收藏
页码：I1119 / I1121
页数：3
相关论文
共 28 条
  • [21] Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials
    Nielsen, Anette Mertz
    Theede, Klaus
    Gluud, Lise Lotte
    Kiszka-Kanowitz, Marianne
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2024, 59 (06) : 669 - 673
  • [22] Endoscopic and histologic outcomes in patients with moderate-to-severe Ulcerative Colitis treated with infliximab: A post hoc analysis of the Phase 3 LIBERTY-UC study
    Colombel, J. F.
    Hanauer, S. B.
    Schreiber, S.
    Danese, S.
    Deepak, P.
    Horst, S. N.
    Jeong, A. L.
    Kim, D. H.
    Lee, Y. N.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i78 - i79
  • [23] Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease
    Atreya, R.
    Kuehbacher, T.
    Waldner, M. J.
    Hirschmann, S.
    Drvarov, O.
    Abu Hashem, R.
    Maaser, C.
    Kucharzik, T.
    Dinter, J.
    Schramm, C.
    Mertens, J.
    Holler, B.
    Moessner, J.
    Suzuki, K.
    Yokoyama, J.
    Terai, S.
    Yoneyama, H.
    Asakura, H.
    Hibi, T.
    Neurath, M. F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S69 - S69
  • [24] SUBMUCOSAL INJECTION OF THE OLIGONUCLEOTIDE STNM01 IS ABLE TO INDUCE CLINICAL REMISSION, MUCOSAL HEALING AND HISTOLOGICAL RESPONSE IN LEFT-SIDED ULCERATIVE COLITIS PATIENTS WITH MODERATE-TO-SEVERE DISEASE
    Atreya, Raja
    Kuehbacher, Tanja
    Waldner, Maximilian
    Hirschmann, Simon
    Drvarov, Oliver
    Abu Hashem, Raed
    Maaser, Christian
    Kucharzik, Torsten
    Dinter, Johanna
    Mertens, Jessica
    Schramm, Christoph
    Holler, Babett
    MSsner, Joachim
    Suzuki, Kenji
    Yokoyama, Junji
    Terai, Shuji
    Yoneyama, Hiroyuki
    Asakura, Hitoshi
    Hibi, Toshifumi
    Neurath, Markus
    GASTROENTEROLOGY, 2017, 152 (05) : S186 - S186
  • [25] SERUM LEUCINE-RICH A 2-GLYCOPROTEIN LEVEL OF LESS THAN 10 MG/ML CAN PREDICT ENDOSCOPIC REMISSION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Horiuchi, Akira
    Horiuchi, Ichitaro
    GASTROENTEROLOGY, 2024, 166 (05) : S517 - S517
  • [26] Prognostic value of short-term endo-histological outcomes in moderate-to severe ulcerative colitis patients on tofacitinib treatment - prospective cohort study
    Resal, T.
    Bacsur, P.
    Farkas, B.
    Ivany, E.
    Balint, A.
    Bosze, Z.
    Fabian, A.
    Bor, R.
    Toth, T.
    Szepes, Z.
    Farkas, K.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1911 - i1911
  • [27] Comparative clinical outcomes of advanced therapy in bio-naïve versus bio-experienced patients hospitalized with Acute Severe Ulcerative Colitis: A retrospective cohort study
    Hwang, S. W.
    Kim, S.
    Lee, C. H.
    Kim, J. W.
    Kim, M. K.
    Lee, S.
    Hong, S. W.
    Park, S. H.
    Yang, D. H.
    Ye, B. D.
    Byeon, J. S.
    Myung, S. J.
    Yang, S. K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1417 - I1418
  • [28] Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis
    Sandborn, W.
    Feagan, B.
    D'Haens, G.
    Levesque, B.
    Pai, R.
    Hanauer, S.
    Wolf, D.
    Vermeire, S.
    Ghosh, S.
    Smith, H.
    Cravets, M.
    Frohna, P.
    Gujrathi, S.
    Aranda, R.
    Olson, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S59 - S60
123